ELANE Genotype

If you or your child have lived with a pattern of fevers, mouth sores, and bacterial infections alongside stubbornly low white cell counts, one gene explains more of these cases than any other. Testing it can turn a vague label like chronic neutropenia into a specific inherited diagnosis.

This is a result you carry from birth, so a single test settles the genetic question for life. But the same change can play out very differently from one person to the next, which is why the result is a starting point rather than a verdict.

What This Gene Actually Does

ELANE (which stands for elastase, neutrophil expressed) carries the instructions for a protein called neutrophil elastase. This protein is made mainly in young cells in your bone marrow that grow into neutrophils, the white blood cells that swallow and kill bacteria. It is packed into tiny storage packets inside those cells and helps destroy invading microbes.

When the gene carries a harmful change, it produces a misshapen protein. The leading explanation is that this misfolded protein triggers a cellular stress response that pushes developing neutrophils to die early, so the bone marrow stalls before it can release mature cells. This mechanism is still debated, and at least one study found a disease-causing change that impaired neutrophil development without triggering that stress response, so it may not apply to every variant. Either way, the end result is a shortage of neutrophils, called neutropenia, and weaker defense against bacteria.

Severe Congenital Neutropenia

Changes in this gene are the most common single genetic cause of severe congenital neutropenia, a deep and lifelong shortage of neutrophils present from infancy, in North American and Western European registries. In one large screening study, harmful changes were found in 41% of congenital neutropenia cases, and about half of congenital neutropenia without other organ involvement traces back to this gene.

The severe form tends to start early and run deep, with recurrent bacterial infections. In a French registry of 143 people with this type of neutropenia, the infections were overwhelmingly bacterial, especially skin infections (cellulitis) and pneumonia, rather than fungal.

What this means for you: a positive result in someone with early, severe infections confirms an inherited driver and signals that close attention to infection prevention and monitoring is warranted, best coordinated with a hematologist.

Cyclic Neutropenia

The same gene also causes cyclic neutropenia, where neutrophils fall and recover on a roughly 21-day rhythm. In that large screening study, harmful changes were found in 55% of cyclic neutropenia cases. During the low points of each cycle, people often develop mouth ulcers, fevers, and infections that clear as counts rebound.

Because the cyclic form is generally milder and comes and goes, it can be missed on a single blood draw. Catching the pattern usually requires blood counts repeated several times over several weeks.

Blood Cancer Risk in the Most Severe Cases

The most serious long-term concern in the severe form is transformation to a bone marrow cancer, either myelodysplastic syndrome or acute myeloid leukemia (blood and marrow cancers, together abbreviated MDS/AML). In a long-running registry of 307 people with this genetic change, 29 of 189 with the congenital form developed MDS/AML, compared with none of the 118 with the cyclic form.

Within the congenital group, the crude cancer frequency varied by the type of change in the gene, though the numbers in each subgroup are small.

Source: SCNIR registry analysis (Makaryan et al., 2012). Certain specific changes clustered with cancer, including C151Y (3 of 4) and G214R (3 of 9). A separate analysis of 403 people found 11 of 44 with termination or frameshift changes developed MDS/AML.

What this means for you: if your result is a higher-risk change or the severe phenotype, ongoing surveillance with a hematologist, including periodic bone marrow checks, becomes part of long-term care rather than a one-time event.

Why the Same Variant Can Mean Different Things

This is not a clean test where one change equals one outcome. Several identical changes, including P139L and common splice-site changes, have been reported in both the severe and cyclic forms, and even relatives carrying the exact same change can have different courses. Some studies flagged mutation-specific patterns, with C151Y and G214R linked to worse outcomes and P139L and S126L to better ones, yet one large mutation-spectrum study found no reliable link between the specific change and the eventual phenotype. The way to hold both findings together is to treat your specific change as a risk signal that sets a range of possibility, not a fixed sentence, because severity is shaped by additional biology beyond the letter change alone.

Beyond Blood: Gums and Immune Effects

The effects can reach beyond infection risk. In a small study of 14 people with the severe form, harmful changes in this gene were associated with more severe gum disease (periodontitis) and an altered mouth bacterial community. A separate case series of three children linked the gene to autoimmune disease alongside neutropenia. These associations rest on small numbers and are best viewed as possibilities to watch rather than certainties.

A One-Time Test You Act On for Years

Because this is a change you inherit and carry from birth, the result does not change and does not need to be repeated. The value comes from what you do with it over time, not from retesting the gene itself.

What does need ongoing tracking is the downstream picture: your neutrophil count, your infection patterns, and, in the severe form, bone marrow surveillance. For a suspected cyclic pattern, guidelines suggest blood counts two to three times a week for at least four to six weeks, since reliably catching the cycle can take a dozen or more counts. For the severe form, regular counts and periodic marrow examinations with a hematologist are the standard rhythm.

What an Unexpected Result Should Prompt

A positive result should lead you to a hematologist or clinical geneticist to confirm the finding and build a monitoring plan. Useful companion tests include repeated neutrophil counts and a differential (a breakdown of the white blood cell types), plus a monocyte count, since a rise in monocytes tends to accompany the severe form. Baseline and periodic bone marrow evaluation, along with discussion of leukemia-risk markers such as acquired CSF3R changes, help gauge and track cancer risk. Cascade testing of biological relatives is also worth discussing.

A negative result does not close the door if neutropenia persists. Other genes cause congenital neutropenia, including HAX1, G6PC3, GATA2, WAS, JAGN1, and SBDS, and broader testing matters here: whole-exome or whole-genome sequencing solved 42% of previously unexplained cases in one series. Routine panels can also miss deep intronic changes buried away from the usual coding regions, so a strongly suggestive picture with a negative standard panel warrants expanded testing.

When Results Can Be Misleading

• Panel coverage: the test detects only the changes it is designed to find. Routine sequencing can miss deep intronic changes, so a negative result does not fully rule out disease in this gene.
• Uncertain variants: a newly seen change may be reported without a known meaning, and simply finding a change does not prove it causes disease. Whether it tracks with neutropenia across the family matters for interpretation.
• Not everyone with a change gets sick: carrying a change does not guarantee neutropenia. A frameshift change in one gene copy was reported in a father and child who both had normal neutrophil counts.
• Ancestry shapes strategy: this gene is the leading cause in Western and North American registries, but in Turkey a different gene, HAX1, was more common, so the best first gene to test depends on background.